Regenxbio (RGNX) Net Cash Flow Growth (1y) (2015 - 2025)
Regenxbio (RGNX) Net Cash Flow Growth (1y) (2015 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,320.50 Bn | 66,320.21 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.93 Bn | 468.14 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 122.22 Bn | 114.98 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 69.96 Bn | 61.21 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 56.07 Bn | 50.89 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.60 Bn | 34.59 Bn | 959.66 Mn | 53.46% |
| 10 | Regenxbio | 510.06 Mn | 279.99 Mn | 21.22 Mn | -2,777.23% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2,777.23% |
| Sep 30, 2025 | -1,708.01% |
| Jun 30, 2025 | 8.45% |
| Mar 31, 2025 | -7.49% |
| Dec 31, 2024 | 104.85% |
| Sep 30, 2024 | 92.62% |
| Jun 30, 2024 | -4,260.98% |
| Mar 31, 2024 | 392.07% |
| Dec 31, 2023 | 13.17% |
| Sep 30, 2023 | -449.65% |
| Jun 30, 2023 | 98.20% |
| Mar 31, 2023 | 82.48% |
| Dec 31, 2022 | -118.37% |
| Sep 30, 2022 | 90.13% |
| Jun 30, 2022 | -104.88% |
| Mar 31, 2022 | -226.64% |
| Dec 31, 2021 | -52.07% |
| Sep 30, 2021 | -2,762.77% |
| Jun 30, 2021 | -238.69% |
| Mar 31, 2021 | -45,476.70% |